Abstract: A cap dispenser assembly with an outer frame, an inner frame, a dispensing shaft, and an actuator. The actuator may be configured to regulate the flow of contents through the cap dispenser assembly while shielding the dispensing shaft or the contents from a wet or moist environment. The actuator may be configured to reciprocate along a dispensing shaft.

Abstract: A cap dispenser assembly comprising an outer frame, an inner frame, a dispensing shaft, and an actuator. The actuator may be configured to regulate the flow of contents through the cap dispenser assembly while shielding the dispensing shaft or the contents from a wet or moist environment. The actuator may be configured to reciprocate along a dispensing shaft.

Abstract: A cap dispenser assembly comprising an outer frame, an inner frame, a dispensing shaft, and an actuator. The actuator may be configured to regulate the flow of contents through the cap dispenser assembly while shielding the dispensing shaft or the contents from a wet or moist environment. The actuator may be configured to reciprocate along a dispensing shaft.

Abstract: This invention relates to the use of biomarker LRG1 as a biomarker for preeclampsia for use from the first trimester. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can predict risk for the future development of preeclampsia or other hypertensive disorders of pregnancy. The predictive test will comprise the measurement of LRG1 protein, peptide fragment, DNA or RNA, from either blood, plasma, serum, urine, saliva or amniotic fluid. The invention provides a method and a test kit to assess the risk of pre-eclampsia in pregnant woman. The method or test can utilise antibodies to measure levels of LGR1 in a sample.

Abstract: The present invention relates to therapies and therapeutic agents for use in the treatment of cardiomyopathies. In particular, the invention is concerned with, but not limited to therapies and therapeutic agents for use in the treatment of hypertrophic cardiomyopathy. Such therapeutic agents comprise hypomethylating agents.

Abstract: This invention relates to the use of biomarker LRG1 as a biomarker for preeclampsia for use from the first trimester. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can predict risk for the future development of preeclampsia or other hypertensive disorders of pregnancy. The predictive test will comprise the measurement of LRG1 protein, peptide fragment, DNA or RNA, from either blood, plasma, serum, urine, saliva or amniotic fluid. The invention provides a method and a test kit to assess the risk of pre-eclampsia in pregnant woman. The method or test can utilise antibodies to measure levels of LGR1 in a sample.

Abstract: The invention provides a method of prognosing and/or diagnosing heart disease or heart failure in a subject, comprising determining the methylation status and/or expression level of at least one methylation marker selected from the group consisting of MFSD2B, miR24-1, TTPA, GALNT15, ITGBL1, SMOC2, MSR1, PVT1, MYOM3, COX17, MYBPC3, HEY2, and MRPL44 wherein the methylation status and/or expression level of at least one methylation marker is indicative of the prognosis and/or diagnosis of said subject. A panel of biomarkers, means, a kit and a device for use in assessing risk of HCM, ISCM and DCM are disclosed.

Abstract: This invention relates to the use of biomarker LRG1 as a biomarker for preeclampsia for use from the first trimester. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can predict risk for the future development of preeclampsia or other hypertensive disorders of pregnancy. The predictive test will comprise the measurement of LRG1 protein, peptide fragment, DNA or RNA, from either blood, plasma, serum, urine, saliva or amniotic fluid. The invention provides a method and a test kit to assess the risk of pre-eclampsia in pregnant woman. The method or test can utilise antibodies to measure levels of LGR1 in a sample.

Abstract: The present invention relates to therapies and therapeutic agents for use in the treatment of cardiomyopathies. In particular, the invention is concerned with, but not limited to therapies and therapeutic agents for use in the treatment of hypertrophic cardiomyopathy. Such therapeutic agents comprise hypomethylating agents.

Abstract: The invention provides methods of detecting a natriuretic protein, a troponin, and galectin-3 in samples from subjects in order to determine risk of developing new onset heart failure with preserved ejection fraction (HFpEF).

Abstract: A fastener for securing a medical or surgical line with respect to a patient, the fastener comprising: an elongate braided tubular sleeve for receiving the line therethrough, the sleeve having a variable length and being capable when lengthened of gripping the line, an attachment arrangement for attaching the sleeve to the patient, and a sensor mounted to the fastener, the sensor being arranged to sense at least one of a physiological parameter of the patient and a parameter in relation to the line.

Abstract: An apparatus includes a task selector to receive an indication of a database task to be performed, wherein the database task includes a set of subtasks; a source selector to receive an indication of a source device to perform the set of subtasks, and to retrieve from the source device an indication of a processing environment currently available within the source device that includes an identity and version level of a database routine of the source device; and an instruction generator to determine a set of languages able to be interpreted by the database routine based on the identity and version level, select a language of the set of languages in which to generate instructions for each subtask based on the processing environment, and generate and transmit the instructions to the source device.

Abstract: A fastener for securing a medical or surgical line with respect to a patient is described. The fastener comprises an elongate braided tubular sleeve for receiving the line therethrough, the sleeve having a first end for fixing adjacent to the patient and a second end for arranging proximal to medical equipment coupled to the line a substantially rigid collar coupled to the sleeve at the first end of the sleeve, an attachment member for securing the fastener with respect to the patient, and a clip coupled to the attachment member. The clip is configured to receive the collar to secure the collar to the clip, and to enable the collar to be released from the clip.

Abstract: The present invention relates to therapies and therapeutic agents for use in the treatment of cardiomyopathies. In particular, the invention is concerned with, but not limited to therapies and therapeutic agents for use in the treatment of hypertrophic cardiomyopathy. Such therapeutic agents comprise hypomethylating agents.

Abstract: An apparatus includes a task selector to receive an indication of a database task to be performed, wherein the database task includes first and second subtasks; a source selector to receive an indication of a source device to perform the first and second subtasks, and to retrieve from the source device an indication of a processing environment currently available within the source device that includes an identity and version level of a database routine of the specified source device; and an instruction generator to determine a set of languages able to be interpreted by the database routine based on the identity and version level, determine whether to perform the first and second subtasks in parallel based on the processing environment, select a language in which to generate instructions to perform the first subtask based on the determination, and generate and transmit the instructions to the source device.

Abstract: An apparatus includes a task selector to receive an indication of a database task to be performed, wherein the database task includes a set of subtasks; a source selector to receive an indication of a source device to perform the set of subtasks, and to retrieve from the source device an indication of a processing environment currently available within the source device that includes an identity and version level of a database routine of the source device; and an instruction generator to determine a set of languages able to be interpreted by the database routine based on the identity and version level, select a language of the set of languages in which to generate instructions for each subtask based on the processing environment, and generate and transmit the instructions to the source device.

Abstract: An apparatus includes a task selector to receive an indication of a database task to be performed, wherein the database task includes first and second subtasks; a source selector to receive an indication of a source device to perform the first and second subtasks, and to retrieve from the source device an indication of a processing environment currently available within the source device that includes an identity and version level of a database routine of the specified source device; and an instruction generator to determine a set of languages able to be interpreted by the database routine based on the identity and version level, determine whether to perform the first and second subtasks in parallel based on the processing environment, select a language in which to generate instructions to perform the first subtask based on the determination, and generate and transmit the instructions to the source device.